From financing to fevers: Lessons of an antimalarial subsidy program

Science

Volumn 338, Issue 6107, 2012, Pages 615-616

  Laxminarayan, Ramanan ^a,b   Arrow, Kenneth ^c   Jamison, Dean ^d   Bloom, Barry R ^e  

^a PRINCETON UNIVERSITY   (United States)

^b Center for Disease Dynamics Economics and Policy   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISIN; ARTEMISININ DERIVATIVE; LACTONE;

ANTIBIOTIC RESISTANCE; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DISEASE SEVERITY; FEVER; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MALARIA; MONOTHERAPY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RURAL POPULATION; TREATMENT PLANNING; URBAN POPULATION; WORLD HEALTH ORGANIZATION; AFRICA SOUTH OF THE SAHARA; ARTICLE; DRUG COMBINATION; DRUG COST; ECONOMICS; FINANCIAL MANAGEMENT; INTERNATIONAL COOPERATION; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP;

AFRICA SOUTH OF THE SAHARA; ANTIMALARIALS; ARTEMISININS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEVER; FINANCING, GOVERNMENT; HUMANS; INTERNATIONAL COOPERATION; LACTONES; MALARIA; PRIVATE SECTOR; PUBLIC HEALTH; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84868229965     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1231010     Document Type: Review

References (16)

1. WHO, Antimalarial Drug Combination Therapy: Report of a WHO Technical Consultation (WHO, Geneva, 2001).
2. WHO, WHO urges regulatory measures to stop marketing of oral artemisinin-based monotherapies and to promote access to artemisinin-based combination therapies (ACTs); www.who.int/malaria/publications/who-measures-to- stop-monotherapies.pdf.
3. H. Noedl et al., N. Engl. J. Med. 359, 2619 (2008).
4. K. J. Arrow, C. B. Panosian, H. Gelband, Eds., Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance (Institute of Medicine, Washington, DC, 2004).
5. O. Adeyi, R. Atun, Lancet 376, 1869 (2010).
6. Independent Evaluation of Phase 1 of the Affordable Medicines Facility - malaria (AMFm): Multi-Country Independent Evaluation Report (ICF International, Calverton, MD, and the London School of Hygiene and Tropical Medicine, London, 2012).
7. AMFm Expert Advisory Group, AMFm, and the Global Fund for AIDS, TB, and Malaria, meeting report of the review of the preliminary independent evaluation of the AMFm Program; www.theglobalfund.org/en/amfm/independentevaluation/.
8. G. Yamey, M. Schäferhoff, D. Montagu, Piloting the Affordable Medicines Facility-malaria: what will success look like? Bull. World Health Organ. 90, 452 (2012).
9. V. D'Acremont et al., PLoS Med. 6, e252 (2009).
10. J. M. Cohen et al., Science 338, 612 (2012).
11. D. H. Hamer et al., J. Am. Med. Assoc. 297, 2227 (2007).
12. L. J. Frost, M. R. Reich, in Access: How Do Good Health Technologies Get to Poor People in Poor Countries? (Harvard Univ. Press, Cambridge MA, 2008).
13. K. Yeboah-Antwi et al., PLoS Med. 7, e1000340 (2010).
14. I. M. C. I. Handbook, Integrated Management of Childhood Illnesses; http://whqlibdoc.who.int/publications/2005/9241546441.pdf.
15. Every Woman Every Child, www.everywomaneverychild.org/.
16. UN Commission sets out plan to make life-saving health supplies more accessible [press release], www.unicef.org/media/media-65942.html.